Britannia Life Sciences Inc.
BLAB
CNSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 1.24M | 1.43M | 1.29M | 1.28M | 1.33M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.24M | 1.43M | 1.29M | 1.28M | 1.33M |
| Cost of Revenue | 518.20K | 468.40K | 419.10K | 769.40K | 443.90K |
| Gross Profit | 723.40K | 965.40K | 871.60K | 514.40K | 887.20K |
| SG&A Expenses | 845.60K | 548.60K | 751.80K | 270.30K | 862.90K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.36M | 1.02M | 1.17M | 1.04M | 1.31M |
| Operating Income | -122.20K | 416.80K | 119.80K | 244.10K | 24.30K |
| Income Before Tax | -24.10K | -685.50K | -499.20K | -4.43M | 278.40K |
| Income Tax Expenses | 43.60K | 108.00K | -9.10K | -297.70K | 36.60K |
| Earnings from Continuing Operations | -67.70K | -793.50K | -490.10K | -4.13M | 241.80K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -30.10K | -82.30K | -49.30K | -251.40K | 151.70K |
| Net Income | -97.80K | -875.80K | -539.40K | -4.38M | 393.50K |
| EBIT | -122.20K | 416.80K | 119.80K | 244.10K | 24.30K |
| EBITDA | -102.90K | 435.10K | 137.10K | 247.90K | 74.30K |
| EPS Basic | 0.00 | -0.01 | 0.00 | -0.03 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | -0.02 | 0.00 |
| EPS Diluted | 0.00 | -0.01 | 0.00 | -0.03 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | -0.02 | 0.00 |
| Average Basic Shares Outstanding | 162.25M | 162.25M | 162.25M | 162.25M | 162.25M |
| Average Diluted Shares Outstanding | 162.25M | 162.25M | 162.25M | 162.25M | 162.25M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |